Loading…
Employees: 2,645
Size R&G PharmaStudies (301333.SZ) is a China Health Care company (Biotechnology) with a market value of $803M, the 2748th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥56.01 on 6 Nov 2026.
Performance Over six months the shares fell 12.2%, against -19.9% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 21.3% over the last twelve months (peer median -3.9%); the operating margin is 11.3% (peer median -61.7%).
Valuation It trades at 38.4× forward earnings against a peer median of 20.0× (2nd most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 16.0 points above its cost of capital (9.3% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥957M | CN¥847M | CN¥741M | CN¥718M | CN¥635M |
| Revenue growth | — | +14% | +3% | +13% | — |
| Gross profit | CN¥317M | CN¥289M | CN¥270M | CN¥280M | CN¥229M |
| EBITDA | n/a | CN¥160M | CN¥157M | CN¥168M | CN¥141M |
| Net income | CN¥117M | CN¥137M | CN¥140M | CN¥163M | CN¥113M |
| Free cash flow | CN¥107M | CN¥116M | CN¥158M | CN¥198M | CN¥119M |
| Capital expenditure | CN¥16.0M | CN¥19.3M | CN¥20.0M | CN¥19.9M | CN¥20.8M |
| Total debt | CN¥50.1M | CN¥17.9M | CN¥71.9M | CN¥8.86M | CN¥15.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301333.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | -7.4% | 10th lowest of 21 |
| 6-month return | -12.2% | -19.9% | 7th highest of 19 |
| Distance from 52-week high | -39.0% | -44.9% | 6th highest of 21 |
| Revenue growth (TTM) | +21.3% | -3.9% | 5th highest of 16 |
| Operating margin | 11.3% | -61.7% | 3rd highest of 18 |
| Forward P/E | 38.4× | 20.0× | 2nd most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 20.1% | 8.8% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +11.8% | +14.7% | 3rd lowest of 6 |
| Hurdle (Req g minus delivered) | +8.3 pp | +6.4 pp | 3rd most demanding of 6 |
| ROIC minus cost of capital | +16.0 pp | -20.3 pp | 2nd highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 38.4× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | n/a | 48.8% | +14.7% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | n/a | -12.3% | -10.9% |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 16.6× | 8.8% | +2.4% |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 20.0× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | n/a | -9.9% | +39.2% |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 135.6× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | n/a | n/a | n/a |